Clinical trials: Eye Abnormalities
Fibromyalgia, Behcet Syndrome
Frequency of Fibromyalgia in Behcet Disease
In various studies, the incidence of fibromyalgia in Behçet's patients is widely distributed. It was aimed to investigate the frequency and severity of fibromyalgia in Behcet disease in province Bursa.
- Trial name
- NCT03514056
- Testing
- group 1:Patients diagnosed with Behcet disease, group 2: Patient diagnosed with fibromyalgia without Behcet disease
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Epiretinal Membrane
Epiretinal Membrane in Patients With DR.
To report the prevalence of ERM among patients with diabetic retinopathy, and the possible associated risk factors.
- Trial name
- NCT07241845
- Testing
- OCT
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Assiut University
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
This is a parallel arm non-randomized dose-escalation, open-label basket exploratory phase 1 clinical trial where Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS) and Leber's hereditary optic…
- Trial name
- NCT06792500
- Testing
- Glycerol Tributyrate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- George Washington University
Bronchopulmonary Dysplasia
Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia
Urinary ascorbyl peroxide level in the first week of life will be a good predictor of Bronchopulmonary dysplasia (BPD) in preterm infants less than 33 weeks of gestation.
- Trial name
- NCT01439295
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- St. Justine's Hospital
Thyroid Eye Disease
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- THRIVE (NCT05176639)
- Testing
- Veligrotug
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 113 people
- Sponsor
- Viridian Therapeutics, Inc.
Keratoconus, Keratoconus, Unspecified, Bilateral
Evaluation of Tomographic and Genetic Aspects of Keratoconus Patients Compared to Sounds Corneas
Evaluation of tomographic (Pentacam) parameters and genetic parameters of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes of keratoconus patients diagnosed by…
- Trial name
- NCT03071302
- Testing
- EVALUATION OF VSX1, SOD1, and TIMP3 genes
- Where
- Brazil
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sao Jose do Rio Preto Medical School
Retinopathy of Prematurity (ROP)
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)
- Trial name
- NCT06717412
- Testing
- Conbercept
- Where
- 3 sites in China
- Volunteers
- 146 people
- Sponsor
- Wang Yusheng
Retinopathy of Prematurity (ROP)
VEGF In Systemic Circulation Of ROP-infants
The purpose of this study is to measure systemic levels of vascular endothelial growth factor (VEGF) and other proteins (e.g. IGF-1) in the systemic circulation of infants with retinopathy of prematurity (ROP) following ocular…
- Trial name
- NCT01470430
- Where
- Germany
- Sponsor
- University Hospital Freiburg
Stargardt Disease
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
- Trial name
- STARLIGHT (NCT05417126)
- Testing
- Gene Therapy-vMCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.
Stargardt Disease
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects.
- Trial name
- GARDian3 (NCT05956626)
- Testing
- OCU410ST
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Ocugen
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07262476
- Testing
- MHB018A injection
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Hearing Disorder
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan
Objective: One objective of this study is to genetically map and identify mutated genes for human hereditary hearing loss. A second objective is to study the function of these genes in the auditory system using mouse models.
- Trial name
- NCT00341874
- Where
- Pakistan
- Volunteers
- 18,009 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Primary Congenital Glaucoma
Iris Tissue in Primary Congenital Glaucoma
To present the histopathological features of the iris tissue in primary congenital glaucoma which may play a role in pathogenesis
- Trial name
- NCT04079725
- Testing
- Combined trabeculotomy-trabeculectomy with mitomycin c
- Volunteers
- 15 people
- Sponsor
- Assiut University
Retinopathy of Prematurity
Vascular Endothelial Growth Factor in Stage V ROP
Vascular Endothelial Growth Factor (VEGF) is a dimeric glycoprotein, naturally expressed in epithelial and tumor cells (1). Normal Retinal vascularization has two phases: In the first fase, cells of mesenquimatous origin form the…
- Trial name
- NCT00500396
- Testing
- Open-Sky Vitrectomy
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back…
- Conditions
- Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
- Trial name
- NCT01553149
- Testing
- Lenalidomide, Pharmacological Study
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Graves Ophthalmopathy
A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy
Intravenous glucocorticoid (IVGC) is an accessible and effective therapy for Graves orbitopathy (GO); the 4.5-g weekly protocol is well studied, but many details of treatment protocols need to be clarified.
- Trial name
- NCT06510114
- Testing
- methylprednisolone(daily scheme), methylprednisolone(weekly scheme)
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Preterm Less Than 32wks With IVH, WMI/PVL, Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE
Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates
Cerebral/Cortical Visual Impairment (CVI) is the leading cause of childhood visual impairment in the United States and other industrialized countries.
- Trial name
- CVI (NCT07275021)
- Testing
- Prospective Clinical and Neurodevelopmental Data Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Retinitis Pigmentosa (RP)
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP.
- Trial name
- NCT07311863
- Testing
- UGX202 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Suzhou UgeneX Therapeutics Co., Ltd.
Retinitis Pigmentosa
Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
The purpose of this trial is to determine whether a nutritional supplement in addition to vitamin A will slow the course of retinitis pigmentosa.
- Trial name
- NCT00000116
- Testing
- Vitamin A, Docosahexaenoic acid, Control fatty acid
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Carol Weigel DiFranco
Retinitis Pigmentosa
Promising ROd-cone DYstrophy Gene therapY
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a…
- Trial name
- PRODYGY (NCT05748873)
- Testing
- SPVN06
- Where
- 6 sites in United States, France
- Volunteers
- 33 people
- Sponsor
- SparingVision